Compare Stocks: ALXO, AVTX, LXRX, and CVAC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$2.05 +3.5%	$1.99	$0.96 ▼ $2.66	$283.47M	0.42	1.03 million shs	628,122 shs
AVTX Avalo Therapeutics	$20.05 -2.4%	$18.89	$8.65 ▼ $24.27	$1.08B	0.8	1.15 million shs	420,239 shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
LXRX Lexicon Pharmaceuticals	$2.32 +0.4%	$2.32	$1.03 ▼ $2.68	$1.03B	1.08	2.96 million shs	1.62 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-1.00%	-3.88%	-1.98%	+4.76%	+80.00%
AVTX Avalo Therapeutics	+4.10%	-0.96%	+5.38%	+27.40%	+116.32%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.70%
LXRX Lexicon Pharmaceuticals	-1.28%	-4.15%	+3.59%	+4.52%	+102.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$2.05 +3.5%	$1.99	$0.96 ▼ $2.66	$283.47M	0.42	1.03 million shs	628,122 shs
AVTX Avalo Therapeutics	$20.05 -2.4%	$18.89	$8.65 ▼ $24.27	$1.08B	0.8	1.15 million shs	420,239 shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
LXRX Lexicon Pharmaceuticals	$2.32 +0.4%	$2.32	$1.03 ▼ $2.68	$1.03B	1.08	2.96 million shs	1.62 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-1.00%	-3.88%	-1.98%	+4.76%	+80.00%
AVTX Avalo Therapeutics	+4.10%	-0.96%	+5.38%	+27.40%	+116.32%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.70%
LXRX Lexicon Pharmaceuticals	-1.28%	-4.15%	+3.59%	+4.52%	+102.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	124.39% Upside
AVTX Avalo Therapeutics	2.86	Moderate Buy	$45.10	124.94% Upside
CVAC CureVac	1.00	Sell	N/A	N/A
LXRX Lexicon Pharmaceuticals	2.25	Hold	$4.55	96.12% Upside

Current Analyst Ratings Breakdown

Latest ALXO, AVTX, LXRX, and CVAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	AVTX Avalo Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$50.00 ➝ $48.00
8/7/2026	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $30.00
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	LXRX Lexicon Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/24/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/23/2026	LXRX Lexicon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	LXRX Lexicon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/6/2026	AVTX Avalo Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/3/2026	LXRX Lexicon Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.98 per share	N/A
AVTX Avalo Therapeutics	$60K	17,921.36	N/A	N/A	$8.37 per share	2.40
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
LXRX Lexicon Pharmaceuticals	$49.80M	20.73	N/A	N/A	$0.39 per share	5.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	11/5/2026 (Estimated)

Latest ALXO, AVTX, LXRX, and CVAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	9.71	9.71
AVTX Avalo Therapeutics	N/A	19.31	19.31
CVAC CureVac	0.03	3.70	3.69
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
AVTX Avalo Therapeutics	87.06%
CVAC CureVac	17.26%
LXRX Lexicon Pharmaceuticals	74.70%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	12.40%
AVTX Avalo Therapeutics	4.46%
CVAC CureVac	2.15%
LXRX Lexicon Pharmaceuticals	14.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	138.28 million	121.13 million	Optionable
AVTX Avalo Therapeutics	40	53.63 million	51.24 million	Not Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
LXRX Lexicon Pharmaceuticals	140	444.96 million	382.66 million	Optionable

ALXO, AVTX, LXRX, and CVAC Headlines

Recent News About These Companies

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Pass Above Two Hundred Day Moving Average - Should You Sell?

August 26 at 2:01 AM | americanbankingnews.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200 Day Moving Average - What's Next?

August 26 at 1:59 AM | marketbeat.com

Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851

August 24 at 5:21 PM | finance.yahoo.com

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

August 24 at 8:30 AM | globenewswire.com

Lexicon Pharmaceuticals Earnings Call: Pipeline Drives Story

August 21, 2026 | tipranks.com

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets

August 19, 2026 | seekingalpha.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving Average - Here's Why

August 18, 2026 | marketbeat.com

Lexicon (LXRX) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Lexicon Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 10, 2026 | seekingalpha.com

Renaissance Technologies LLC Increases Holdings in Lexicon Pharmaceuticals, Inc. $LXRX

August 10, 2026 | marketbeat.com

HC Wainwright Issues Positive Forecast for LXRX Earnings

August 10, 2026 | marketbeat.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to "Sell" at Wall Street Zen

August 8, 2026 | marketbeat.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Announces Earnings Results, Misses Estimates By $0.01 EPS

August 7, 2026 | marketbeat.com

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

August 6, 2026 | marketbeat.com

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2026 | zacks.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down on Disappointing Earnings

August 6, 2026 | marketbeat.com

Lexicon: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Lexicon Pharmaceuticals Reports Q2 2026 Results; Completes Enrollment in Phase 3 SONATA-HCM Study and Advances ZYNQUISTA NDA Resubmission

August 6, 2026 | quiverquant.comQ

Lexicon Pharmaceuticals Q2 revenue falls to $0.7 million amid clinical updates

August 6, 2026 | quiverquant.comQ

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

August 6, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO, AVTX, LXRX, and CVAC Company Descriptions

ALX Oncology NASDAQ:ALXO

$2.05 +0.07 (+3.54%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 -0.01 (-0.29%)

As of 07:56 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Avalo Therapeutics NASDAQ:AVTX

$20.05 -0.50 (-2.43%)

Closing price 04:00 PM Eastern

Extended Trading

$20.00 -0.05 (-0.27%)

As of 07:35 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 08/26/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.32 +0.01 (+0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$2.32 0.00 (-0.22%)

As of 07:59 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALXO, AVTX, LXRX, and CVAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALXO, AVTX, LXRX, and CVAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALXO, AVTX, LXRX, and CVAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO, AVTX, LXRX, and CVAC Company Descriptions

ALX Oncology NASDAQ:ALXO

Avalo Therapeutics NASDAQ:AVTX

CureVac NASDAQ:CVAC

Lexicon Pharmaceuticals NASDAQ:LXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALXO, AVTX, LXRX, and CVAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALXO, AVTX, LXRX, and CVAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALXO, AVTX, LXRX, and CVAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO, AVTX, LXRX, and CVAC Company Descriptions

ALX Oncology NASDAQ:ALXO

Avalo Therapeutics NASDAQ:AVTX

CureVac NASDAQ:CVAC

Lexicon Pharmaceuticals NASDAQ:LXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools